Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Owen

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Blood|December 30, 2017
Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndromeDorota M Rowczenio, Shelly Pathak, Juan I Arostegui, et al.
The Lancet. Oncology|September 24, 2013
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trialsJoanne S Haviland, J Roger Owen, John A Dewar, et al.
Blood|January 18, 2006
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemiaSteven P Treon, Morie A Gertz, Meletios Dimopoulos, et al.
British Journal of Haematology|March 14, 2021
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma TrialRakesh Popat, Nicholas Counsell, Ruth de Tute, et al.
British Journal of Haematology|March 2, 2021
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON studyMarquita Camilleri, Maria Cuadrado, Elizabeth Phillips, et al.
BMJ Open|June 2, 2022
<i>F</i>railty-adjusted therapy <i>i</i>n <i>T</i>ransplant <i>N</i>on-<i>E</i>ligible patient<i>s</i> with newly diagno<i>s</i>ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trialAmy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, et al.
BMJ Open|November 17, 2022
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trialKara-Louise Royle, Amy Beth Coulson, Karthik Ramasamy, et al.
Haematologica|October 16, 2012
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemiaFlorence Nguyen-Khac, Jerome Lambert, Elise Chapiro, et al.
Blood Advances|November 1, 2021
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignanciesConstantine S Tam, Meletios Dimopoulos, Ramon Garcia-Sanz, et al.
Leukemia|November 26, 2022
Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's MacroglobulinemiaIrene Dogliotti, Cristina Jiménez, Marzia Varettoni, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Blood|December 30, 2017
Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndromeDorota M Rowczenio, Shelly Pathak, Juan I Arostegui, et al.
The Lancet. Oncology|September 24, 2013
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trialsJoanne S Haviland, J Roger Owen, John A Dewar, et al.
Blood|January 18, 2006
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemiaSteven P Treon, Morie A Gertz, Meletios Dimopoulos, et al.
British Journal of Haematology|March 14, 2021
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma TrialRakesh Popat, Nicholas Counsell, Ruth de Tute, et al.
British Journal of Haematology|March 2, 2021
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON studyMarquita Camilleri, Maria Cuadrado, Elizabeth Phillips, et al.
BMJ Open|June 2, 2022
<i>F</i>railty-adjusted therapy <i>i</i>n <i>T</i>ransplant <i>N</i>on-<i>E</i>ligible patient<i>s</i> with newly diagno<i>s</i>ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trialAmy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, et al.
BMJ Open|November 17, 2022
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trialKara-Louise Royle, Amy Beth Coulson, Karthik Ramasamy, et al.
Haematologica|October 16, 2012
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemiaFlorence Nguyen-Khac, Jerome Lambert, Elise Chapiro, et al.
Blood Advances|November 1, 2021
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignanciesConstantine S Tam, Meletios Dimopoulos, Ramon Garcia-Sanz, et al.
Leukemia|November 26, 2022
Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's MacroglobulinemiaIrene Dogliotti, Cristina Jiménez, Marzia Varettoni, et al.
Pageof 8